US 12,247,071 B2
Anti-TNF alpha antibody formulations
William J. Callahan, Thousand Oaks, CA (US); Rahul Rajan Kaushik, Newbury Park, CA (US); and Joy Brennan, Thousand Oaks, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Aug. 19, 2022, as Appl. No. 17/820,958.
Application 17/820,958 is a continuation of application No. 16/471,492, abandoned, previously published as PCT/US2017/067723, filed on Dec. 20, 2017.
Claims priority of provisional application 62/437,640, filed on Dec. 21, 2016.
Prior Publication US 2023/0151086 A1, May 18, 2023
Int. Cl. C07K 16/24 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01)
CPC C07K 16/241 (2013.01) [A61K 47/10 (2013.01); A61K 47/183 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01)] 1 Claim
 
1. A formulation comprising about 180 mg/mL adalimumab, 20 mM glutamate, and 160 mM monoethanolamine (MEA).